Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 1...( Dr. Mark Hurtt Chief Medical Office...),Health

Dr. Mark Hurtt, Chief Medical Officer, to present interim results of the

Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury

HOPKINTON, Mass., April 9, 2008 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced that on April 15, 2008, Dr. Mark Hurtt, Chief Medical Officer, will discuss the CETHRIN development program as a member of an expert panel on Spinal Cord Injury Research during a congressional briefing on Capitol Hill focused on "Rapid Advancements in Paralysis Research." In addition, Dr. Hurtt will present interim results of the CETHRIN Phase I/IIa clinical trial in acute spinal cord injury during a plenary session on April 13, 2008 at the "Working 2 Walk" Science and Education Symposium in Washington, DC.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

Dr. Hurtt's presentation will review the safety and efficacy results from the first 37 patients in Alseres' CETHRIN Phase I/IIa study. The data indicated that CETHRIN was safe and well tolerated. There was improvement using the American Spinal Injury Association (ASIA) impairment scale in combined thoracic and cervical patients approximately four times greater than the conversion rate for patients in a comparable historical study who did not receive CETHRIN. When analyzed as a subset, patients with cervical (neck) injuries who were treated with CETHRIN showed improvement using the same impairment scale that was almost seven times greater than the full patient group treated with only the standard of care reported in the comparable study. In subjects with cervical injuries, the interim efficacy data also suggest that t
'/>"/>